Sclerosis News and Research

RSS
Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Preclinical data from Teva's COPAXONE study on multiple sclerosis

Preclinical data from Teva's COPAXONE study on multiple sclerosis

UH scientists recommend new drug strategies for chronic diseases

UH scientists recommend new drug strategies for chronic diseases

New metabolic pathway for controlling brain inflammation

New metabolic pathway for controlling brain inflammation

Oral laquinimod shows promise against multiple sclerosis

Oral laquinimod shows promise against multiple sclerosis

Melbourne Brain Centre to open on Monday

Melbourne Brain Centre to open on Monday

Circadian disruption and sleep restriction increase risk of MS in teens

Circadian disruption and sleep restriction increase risk of MS in teens

Brain tumour discovery offers drug treatment hope

Brain tumour discovery offers drug treatment hope

Brain stem cell treatment for multiple sclerosis

Brain stem cell treatment for multiple sclerosis

Scientists characterize and isolate potential stem cells to treat MS, myelin disorders

Scientists characterize and isolate potential stem cells to treat MS, myelin disorders

U of U researchers receive NIH grant to uncover viral cause of MS

U of U researchers receive NIH grant to uncover viral cause of MS

Peanut allergy could be switched off

Peanut allergy could be switched off

AAN Foundation launches new PSA on finding cure for brain disease

AAN Foundation launches new PSA on finding cure for brain disease

COPAXONE reduces loss of brain volume in patients with RRMS

COPAXONE reduces loss of brain volume in patients with RRMS

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR receives U.S. patent allowance for CTP-modified interferons

Researchers identify cellular pathway to potentially block disease-inducing inflammation

Researchers identify cellular pathway to potentially block disease-inducing inflammation

Teriflunomide drug reduces relapse rate of people with MS

Teriflunomide drug reduces relapse rate of people with MS

New review finds inconsistency in studies that examine link between CCSVI and MS

New review finds inconsistency in studies that examine link between CCSVI and MS

Roundup: Blue Shield of Calif. drops coverage of controversial drug in breast cancer treatment; Perry presses stem cell therapy

Roundup: Blue Shield of Calif. drops coverage of controversial drug in breast cancer treatment; Perry presses stem cell therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.